• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Proscia Secures $50M to Accelerate AI-Driven Digital Pathology

by Fred Pennic 03/19/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
FDA Clears Proscia's AI-Powered Digital Pathology Solution for Cancer Diagnosis

What You Should Know: 

– Proscia, a software company focused on digitizing and applying AI to pathology, has announced a $50M funding round, bringing its total capital raised to $130M. 

– The funding, led by Insight Partners, AI Capital Partners, and Triangle Peak Partners, will be used to further expand the adoption of Proscia’s platform, integrate more AI capabilities, and leverage strategic OEM partnerships with industry giants like Agilent Technologies and Siemens Healthineers.

– The investment comes on the heels of a year of record growth for the company, which now counts 16 of the top 20 pharmaceutical companies as users and anticipates over 22,000 patient diagnoses daily through its Concentriq platform.

AI-Driven Pathology Solution 

Concentriq, Proscia’s flagship platform, is positioned as the only AI-driven pathology solution that supports the entire precision medicine value chain. It facilitates drug discovery, accelerates diagnostics, and connects life sciences organizations and laboratories to match patients with targeted treatments. The platform’s AI capabilities, including Concentriq Embeddings, which utilizes foundation models to accelerate AI development by 13x, empower researchers and data scientists to develop and deploy algorithms for biomarker discovery, clinical trials, and companion diagnostics.

The company’s precision medicine AI portfolio offers a comprehensive suite of applications designed to enhance diagnostic accuracy and efficiency. Proscia’s solutions are already trusted by a global network of diagnostic laboratories and pharmaceutical companies, with FDA 510(k) clearance and CE-IVDR certification for its diagnostic software.

“We are living through an extraordinary moment in medicine,” said David West, Proscia’s CEO. “Demand for advanced diagnostics is surging, digital pathology is gaining global traction, and AI is moving faster than the boldest predictions made just a few years ago. Patients are waiting to realize the future of precision medicine. With this investment, we will ensure that more pathologists and scientists can deliver it.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Digital Pathology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |